Effective delivery of the anti-mycobacterial peptide NZX in mesoporous silica nanoparticles

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Effective delivery of the anti-mycobacterial peptide NZX in mesoporous silica nanoparticles. / Tenland, Erik; Pochert, Alexander; Krishnan, Nitya; Rao, Komal Umashankar; Kalsum, Sadaf; Braun, Katharina; Glegola-Madejska, Izabela; Lerm, Maria; Robertson, Brian D.; Lindén, Mika; Godaly, Gabriela.

I: PLoS ONE, Vol. 14, Nr. 2, e0212858, 26.02.2019.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Tenland, E, Pochert, A, Krishnan, N, Rao, KU, Kalsum, S, Braun, K, Glegola-Madejska, I, Lerm, M, Robertson, BD, Lindén, M & Godaly, G 2019, 'Effective delivery of the anti-mycobacterial peptide NZX in mesoporous silica nanoparticles', PLoS ONE, vol. 14, nr. 2, e0212858. https://doi.org/10.1371/journal.pone.0212858

APA

Tenland, E., Pochert, A., Krishnan, N., Rao, K. U., Kalsum, S., Braun, K., Glegola-Madejska, I., Lerm, M., Robertson, B. D., Lindén, M., & Godaly, G. (2019). Effective delivery of the anti-mycobacterial peptide NZX in mesoporous silica nanoparticles. PLoS ONE, 14(2), [e0212858]. https://doi.org/10.1371/journal.pone.0212858

CBE

Tenland E, Pochert A, Krishnan N, Rao KU, Kalsum S, Braun K, Glegola-Madejska I, Lerm M, Robertson BD, Lindén M, Godaly G. 2019. Effective delivery of the anti-mycobacterial peptide NZX in mesoporous silica nanoparticles. PLoS ONE. 14(2):Article e0212858. https://doi.org/10.1371/journal.pone.0212858

MLA

Vancouver

Author

Tenland, Erik ; Pochert, Alexander ; Krishnan, Nitya ; Rao, Komal Umashankar ; Kalsum, Sadaf ; Braun, Katharina ; Glegola-Madejska, Izabela ; Lerm, Maria ; Robertson, Brian D. ; Lindén, Mika ; Godaly, Gabriela. / Effective delivery of the anti-mycobacterial peptide NZX in mesoporous silica nanoparticles. I: PLoS ONE. 2019 ; Vol. 14, Nr. 2.

RIS

TY - JOUR

T1 - Effective delivery of the anti-mycobacterial peptide NZX in mesoporous silica nanoparticles

AU - Tenland, Erik

AU - Pochert, Alexander

AU - Krishnan, Nitya

AU - Rao, Komal Umashankar

AU - Kalsum, Sadaf

AU - Braun, Katharina

AU - Glegola-Madejska, Izabela

AU - Lerm, Maria

AU - Robertson, Brian D.

AU - Lindén, Mika

AU - Godaly, Gabriela

PY - 2019/2/26

Y1 - 2019/2/26

N2 - Background Intracellular delivery of antimicrobial agents by nanoparticles, such as mesoporous silica particles (MSPs), offers an interesting strategy to treat intracellular infections. In tuberculosis (TB), Mycobacterium tuberculosis avoids components of the immune system by residing primarily inside alveolar macrophages, which are the desired target for TB therapy. Methods and findings We have previously identified a peptide, called NZX, capable of inhibiting both clinical and multi-drug resistant strains of M. tuberculosis at therapeutic concentrations. In this study we analysed the potential of MSPs containing NZX for the treatment of tuberculosis. The MSPs released functional NZX gradually into simulated lung fluid and the peptide filled MSPs were easily taken up by primary macrophages. In an intracellular infection model, the peptide containing particles showed increased mycobacterial killing compared to free peptide. The therapeutic potential of peptide containing MSPs was investigated in a murine infection model, showing that MSPs preserved the effect to eliminate M. tuberculosis in vivo. Conclusions In this study we found that loading the antimicrobial peptide NZX into MSPs increased the inhibition of intracellular mycobacteria in primary macrophages and preserved the ability to eliminate M. tuberculosis in vivo in a murine model. Our studies provide evidence for the feasibility of using MSPs for treatment of tuberculosis.

AB - Background Intracellular delivery of antimicrobial agents by nanoparticles, such as mesoporous silica particles (MSPs), offers an interesting strategy to treat intracellular infections. In tuberculosis (TB), Mycobacterium tuberculosis avoids components of the immune system by residing primarily inside alveolar macrophages, which are the desired target for TB therapy. Methods and findings We have previously identified a peptide, called NZX, capable of inhibiting both clinical and multi-drug resistant strains of M. tuberculosis at therapeutic concentrations. In this study we analysed the potential of MSPs containing NZX for the treatment of tuberculosis. The MSPs released functional NZX gradually into simulated lung fluid and the peptide filled MSPs were easily taken up by primary macrophages. In an intracellular infection model, the peptide containing particles showed increased mycobacterial killing compared to free peptide. The therapeutic potential of peptide containing MSPs was investigated in a murine infection model, showing that MSPs preserved the effect to eliminate M. tuberculosis in vivo. Conclusions In this study we found that loading the antimicrobial peptide NZX into MSPs increased the inhibition of intracellular mycobacteria in primary macrophages and preserved the ability to eliminate M. tuberculosis in vivo in a murine model. Our studies provide evidence for the feasibility of using MSPs for treatment of tuberculosis.

U2 - 10.1371/journal.pone.0212858

DO - 10.1371/journal.pone.0212858

M3 - Article

C2 - 30807612

AN - SCOPUS:85062069519

VL - 14

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 2

M1 - e0212858

ER -